Sakar Healthcare Limited (NSE:SAKAR)

Market Cap	23.90B +165.4%
Revenue (ttm)	3.03B +48.1%
Net Income	428.65M +119.8%
EPS	19.32 +118.6%
Shares Out	22.25M
PE Ratio	55.57
Forward PE	46.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,467
Open	1,075.70
Previous Close	1,075.70
Day's Range	1,055.75 - 1,085.00
52-Week Range	352.50 - 1,229.85
Beta	0.45
Analysts	n/a
Price Target	n/a
Est. Earnings	Feb 5, 2027

About Sakar Healthcare

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company offers general and oncology products in various forms, such as liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. It also exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedab...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 435
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SAKAR

Financial Performance

In fiscal year 2026, Sakar Healthcare's revenue was 2.53 billion, an increase of 41.89% compared to the previous year's 1.78 billion. Earnings were 304.85 million, an increase of 74.18%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 12, 2026

Data Sources Report a data error